Original articlesBreast tumorsSurvival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
Breast tumors
Under an Elsevier user license
open archive
Key words
survival
homologuous recombinant deficiency
neoadjuvant chemotherapy
carboplatin
triple-negative breast cancer
Cited by (0)
Results were presented in part at the ASCO Annual Meeting 2015, Chicago, IL, USA, 29 May–2 June 2015, and the 39th San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 6–10 December 2016 and ESMO Annual Meeting 2017, Madrid, 7–12 September 2017.
Copyright © 2018 THE AUTHORS. Published by Elsevier Ltd. All rights reserved.